Medical news network August 9th day before, a new drug for the treatment of bone marrow fibrosis (Lu Wei Jie Ke phosphate ruxolitinib) officially listed in China. Bone marrow fibrosis is a malignant hematologic tumor. Lu Yi is the only targeted drug for its pathogenesis. The current director of Hematology branch committee, China Academy of Medical Sciences, Beijing Union Medical College Hospital hematology hematology Institute Professor Wang Jianxiang vice director of the Chinese Medical Association said, in the current clinical trials, whether in symptom control, or life expectancy, Lu ruxolitinib shows effectiveness.
Bone marrow fibrosis affects the systemic hematopoietic system
For many people, myelofibrosis is a relatively new disease that literally doesn't seem to be a very serious disease. In fact, myelofibrosis is a malignant form of hematologic malignancies. According to Wang Jianxiang introduction, bone marrow fibrosis is a myeloproliferative neoplasm, relatively rare, will affect the human hematopoietic system, which causes a series of abnormal and hematopoietic related symptoms, such as anemia, obvious splenomegaly, abdominal distension, early satiety, and some related systemic symptoms, such as obvious weight loss, night sweats, and even some patients will be transformed into acute leukemia. Studies have shown that long-term abnormalities in hematopoietic function make it possible for myelofibrosis to reach 20% in 10 years.
Bone marrow fibrosis not only affects the patient's life span, but more importantly, the disease has very serious systemic symptoms, resulting in poor quality of life of patients, affecting life confidence. Therefore, the treatment of bone marrow fibrosis, not only to improve the disease process and prolong survival, but also to better improve the symptoms of patients and improve the quality of life." Wang Jianxiang expresses.
According to Chinese Academy of Medical Sciences, Beijing Union Medical College of Hematology Institute Deputy Dean Professor Xiao Zhijian introduction, the whole bone marrow fibrosis. The median survival time was 5.7 years, the survival of high-risk patients is only 2.3 years. At present, the cause of myelofibrosis is unclear, and the exact high risk factors are exposure to chemicals or exposure to nuclear radiation.
Targeted drugs improve symptoms and prolong life
The short-term goal of bone marrow fibrosis is to reduce the spleen, reduce the burden of disease and improve the quality of life. The long-term goal is to prolong survival and prevent or reverse the progression of myelofibrosis.
Prior to this, there was no very effective way to control bone marrow fibrosis, and only traditional drugs could be used to control the progress of the disease or relieve symptoms. Allogeneic hematopoietic stem cell transplantation is the only possible treatment for myelofibrosis, but many patients do not.
The new target drug, Lu Yi, which is listed in China, is a JAK inhibitor developed for the abnormal activation of JAK-STAT signaling pathway, a pathogenesis of myelofibrosis. "Lu ruxolitinib is the advent of scientific understanding of the pathogenesis and the signal transduction pathway of bone marrow fibrosis based on the development of targeted therapies for this pathway, specifically blocking the signal pathway, to achieve the purpose of disease control. The effectiveness of the treatment has been shown in current clinical trials." Wang Jianxiang introduction, Lu Yi can delay the process of bone marrow fibrosis, prolong survival, can also improve the symptoms of patients, improve quality of life.
It is understood that Lu ruxolitinib has become the European Society for Medical Oncology (ESMO), the UK, Germany, the United States National Comprehensive Cancer Network (NCCN) bone marrow fibrosis therapeutics guidelines recommend, and won the "primary myelofibrosis diagnosis and treatment of China expert consensus" (2015 Edition) recommended.
Standardized diagnosis and treatment should be further promoted
The onset of myelofibrosis is occult. About 25% of the patients have no symptoms at diagnosis and are diagnosed in the daily physical examination and then diagnosed at the Department of hematology. So, how do you detect it early? Xiao Zhijian said that if the weight loss, night sweats, skin itching and unexplained, face and hands, but not necessarily high temperature hot flashes, the left side of the abdomen can touch bag piece, if the above symptoms, patients must be to the regular hospital department of Hematology routine, and under the guidance of a doctor in a step by bone marrow biopsy. Early diagnosis and early treatment can significantly improve the patient's survival." Xiao Zhijian expresses.
Wang Jianxiang also emphasized the importance of standardized diagnosis and treatment of myelofibrosis. Compared with the bone marrow biopsy, bone marrow biopsy is bone marrow tissue, can see the structure of the original state of the bone marrow biopsy examination, more accurate, but also for the degree of fibrosis rating, most medical institutions still do not.
About standardized medication, Xiao Zhijian stressed that, at present, patients generally need lifelong medication, if the withdrawal, the former symptoms will occur again, such as the spleen again become larger, emaciated, night sweats and so on. If there is a special reason to stop the drug, must be under the guidance of a doctor, can not suddenly stop their own medicine, so as not to cause harm to patients.
It is reported that the China Charity Federation Jie Ke Wei patient assistance project will start in the year, to help meet the conditions of the implementation of standardized treatment in patients with aid.
